Results of the of neoadjuvant polychemotherapy in the combined treatment of gastric cancer

Objective. To analyze and systematize data on the treatment results, and morphological changes in neoplasms (N) in association with the use of neoadjuvant polychemotherapy (NPCT) in a complex treatment of gastric cancer (GC).

Materials and methods. Original publications containing information on the use of NPCT in the complex treatment of GC, pathomorphological changes (PC) of neoplasms in the course of this treatment, deposited in the resources of PubMed and the information portal eLIBRARY.RU, were studied. Olympus CX41 RF microscope, Olympus SC20 digital camera, Statistica 10.0 software package, Pearson criterion, Mann Whitney criterion, paired t-test were used.

Results. The most important aspects concerning the use of NPCT in complex treatment of GC were highlighted, and the treatment results and morphological changes of neoplasms in patients with this pathology in the course of this treatment were analyzed.

Conclusion. Currently, in the treatment of resectable GC, preference should be given to a combination of NPCT followed by radical surgery. The level of N pathomorphism and changes in neutrophil-lymphocyte ratio (NRL) might be promising criteria for assessing the effectiveness of the chosen chemotherapy (CT) regimen, as well as its subsequent use in the adjuvant setting.

1. Lyadov VK, Pardabekova OA, Lyadova MA. Perioperative chemotherapy for stomach cancer: the state of the problem. Modern oncology. 2018;20(2):56-60. (In Russ.). DOI: https://doi.org/10.26442/1815-1434_2018.2.56-60

2. Mironova DYu, Skoropad VYu, Kolobaev IV, Ivanov SA, Kaprin AD. Assessment of the safety and feasibility of neoadjuvant chemotherapy (2 cycles of FLOT chemotherapy + chemoradiotherapy) followed by surgery in the treatment of locally advanced gastric cancer. Siberian journal of oncology. 2024;23(1):45-52. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2024-23-1-45-52

3. Mantsyrev EO, Privalov AV, Kuvaev SV, Semikopov K. V., Gavrishkin I. A. Evaluation of the efficiency of perioperative chemotherapy in the complex treatment of gastric cancer. Ural medical journal. 2021;20(2):17-22. DOI: https://doi.org/10.52420/2071-5943-2021-20-2-17-22

4. Augustinovich AF, Afanasyev SG, DobrodeevA Yu, Volkov MU, Kostromitsky DN, Spirina LV, et al. Immediate efficacy and toxicity of total neoadjuvant chemotherapy for resectable stomach cancer. Siberian Journal of Oncology. 2022;21(1):11-19. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2022-21-1-11-19

5. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial The Lancet. 2019;393(10184):1948-1957.

6. Nguyen HV, Nguyen HV, Nguyen LT, Pham NQ, Nguyen HX, Nguyen HX, et al. A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy. Case reports in oncological medicine. 2019 Nov 29:1352173. DOI: https://doi.org/10.1155/2019/1352173

7. Trusilova EV, Besova NS, Gorbunova VA, Bondarenko YuV. Efficacy and toxicity of FOLFIRINOX chemotherapy in patients with disseminated gastric cancer. Preliminary results. Effective pharmacotherapy. 2013;4(46):6-13. [date of access 2025 May 10]. Available from: https://umedp.ru/upload/iblock/f77/f7718c31025af1430c9a9127f5202e4a.pdf (In Russ.).

8. Lisayeva AA, Vishnevskaya YaV, Roshchin EM, Komov DV, Kolyadina I.V. Therapeutic pathomorphism of malignancies: Clinical and morphological criteria. Classifications. Prognostic value of therapeutic pathomorphism in breast cancer and other tumors. Tumors of female reproductive system. 2011;(4):19-23. (In Russ.).

9. Skoropad VYu, Kudriavtsev DD, Titova LN, Moserov SA, Agababyan TA, Ivanov SA, Kaprin AD. Pathological complete response to neoadjuvant chemoradiotherapy in patients with locally advanced gastric cancer. Siberian journal of oncology. 2020;19(3):38-46. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2020-19-3-38-46

10. Bogomolova IA, Dolgova DR, Kolodiy IO, Antoneeva II. Prediction of sensitivity of patients with colorectal cancer to chemotherapy using the FOLFOX/XELOX regimen based on the neutrophil-to-lymphocyte ratio. Volga Region Oncological Bulletin. 2023;55(3). (In Russ.).

11. Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on Neutrophil Function in Severe Inflammation. Front Immunol. 2018 Oct 2;9:2171. DOI: https://doi.org/10.3389/fimmu.2018.02171

12. Gunaldi M, Goksu S, Erdem D, Gunduz S, Okuturlar Y, Tiken E, et al. Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study. Int J Clin Exp Med. 2015 Apr 15;8(4):5937-5942. [date of access 2025 May 10]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4483800/